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Introduction: The information regarding therapeutically relevant 
genomic alterations in small cell lung cancer (SCLC) is not well 
developed. We analyzed the SCLC genome using an integrative 
approach to stratify the targetable alterations.
Methods: We performed whole exon sequencing (n = 51) and copy 
number analysis (n =47) on surgically resected tumors and matched 
normal tissue samples from treatment-naive Japanese SCLC patients.
Results: The demographics of the 51 patients included in this study 
were as follows: median age, 67 years (range, 42–86 years); female, 9 
(18%); history of smoking, 50 (98%); and pathological stage I/II/III/
IV, 28/13/9/1, respectively. The average number of nonsynonymous 
mutations was 209 (range, 41–639; standard deviation, 130). We 
repeatedly confirmed the high prevalence of inactivating mutations 
in TP53 and RB1, and the amplification of MYC family members. In 
addition, genetic alterations in the PI3K/AKT/mTOR pathway were 
detected in 36% of the tumors: PIK3CA, 6%; PTEN, 4%; AKT2, 9%; 
AKT3, 4%; RICTOR, 9%; and mTOR, 4%. Furthermore, the indi-
vidual changes in this pathway were mutually exclusive. Importantly, 
the SCLC cells harboring active PIK3CA mutations were potentially 
targetable with currently available PI3K inhibitors.
Conclusions: The PI3K/AKT/mTOR pathway is distinguishable in 
SCLC genomic alterations. Therefore, a sequencing-based compre-
hensive analysis could stratify SCLC patients by potential therapeu-
tic targets.
Key Words: Lung cancer, Small cell, Genome, Comprehensive, 
PI3K/AKT/mTOR.
(J Thorac Oncol. 2014;9: 1324–1331)
Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers,1 and it is an exceptionally aggres-
sive malignancy with a high proliferative index and an unusu-
ally strong predilection for early metastasis.2 Despite extensive 
basic and clinical research over the past 30 years, little prog-
ress has been made2 in treating this disease.
A better understanding of the genomic changes in SCLC 
is essential to identify new therapeutic targets. Genomic analyses 
have revealed genetically altered therapeutic targets in lung ade-
nocarcinoma3–5 and squamous cell lung carcinoma.6 However, a 
systematic genomic analysis of SCLC is difficult because this 
cancer subtype is rarely treated surgically, resulting in the lack of 
suitable tumor specimens for comprehensive analysis.
Two reports regarding the comprehensive genomic 
analysis of SCLC with a relatively small number of samples 
have been published recently. These reports suggested that 
transcriptional deregulation (i.e., via RB1, SOX2, MYC family 
members and chromatin modifiers) might play a role in SCLC 
biology.7,8 However, to date, attempts to develop targeted 
therapies toward these transcriptional deregulations have had 
limited success.
Activating alterations to oncogenes, such as receptor 
tyrosine kinases (RTKs) and PI3K/AKT/mTOR pathway pro-
teins,9–13 are regarded as successful therapeutic targets. We 
conducted a comprehensive genomic study in over 50 SCLC 
cases, and we found a higher penetrance of activating altera-
tions of the PI3K/AKT/mTOR pathway that act in a mutually 
exclusive manner.
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PATIENTS AND METHODS
Samples
This study was approved by the Institutional Review 
Board (IRB) of the National Cancer Center, Japan (IRB num-
ber: 2011-201). All data used in this study were obtained from 
a database at the Division of Thoracic Oncology, National 
Cancer Center Hospital East, Kashiwa, Japan.
From July 1992 to March 2012, we consecutively col-
lected 1042 SCLC cases at our hospital. Fifty-five of these 
cases were included in the current study based on the fol-
lowing criteria: a surgical resection or mediastinoscopy was 
performed; a re-review confirmed a pathological diagnosis of 
SCLC; the tumor specimens contained a minimum of 70% 
tumor cells; enough tissue was obtained for a comprehen-
sive analysis; the patient did not receive any neoadjuvant 
treatment; and the corresponding normal tissue, which was 
obtained from paraffin-embedded blocks of resected lung tis-
sue that was microscopically free of cancer cells, was also 
available for analysis. We analyzed the exomes of these 55 
samples to assess their mutational burden.
Depending on the tissue size, three to six sections (10 
μm thickness) were cut. For the tumors showing a combined 
SCLC and other histology, only the SCLC compartment was 
dissected and used for analysis. Total DNA was obtained from 
formalin- (n = 43) or methanol-fixed (n = 12) paraffin-embed-
ded tumors and matched normal tissue samples. All patients 
(100%) were Japanese.
Among these 55 cases, four exome data sets did not meet 
the sequence quality requirement and were excluded from fur-
ther analyses. In addition, 48 samples received copy number 
analysis using single nucleotide polymorphism array data.
Procedures
The detailed experimental procedures are described in 
the Supplemental Information section (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A625)
Whole Exon Sequencing and 
Copy Number Analysis
The Absolutely RNA FFPE kit (modified protocol for 
DNA extraction, Agilent Technologies, Santa Clara, CA) 
was used to prepare the DNA. Using 1 μg of dsDNA, quan-
tified by Quant-iT PicoGreen dsDNA Reagent and Kits (Life 
Technologies, Carlsbad, CA), the exome-sequencing libraries 
were prepared. All exomes were captured using the SureSelect 
Human All Exon V4+UTRs Kit (Agilent Technologies) (71 mb). 
The exome capture libraries were sequenced by HiSeq 2000 
(Illumina, San Diego, CA) to generate 100-bp paired-end data.
The Illumina HumanOmniExpress-FFPE BeadChip 
assay was used to analyze the genotype, DNA copy num-
ber, and loss of heterozygosity (LOH) in 48 primary-normal 
paired samples. All samples, except for 1 (n = 47), passed our 
quality control metrics for sample identity and data quality. 
A subset of 693,000 high-quality single nucleotide polymor-
phisms was selected for all analyses (Supplemental Figure 1, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A626). A gene was considered copy number amplified if the 
calculated copy number in a sample was more than or equal to 
4, and a gene was considered copy loss if the copy number in 
a sample was 0. Recurrent genomic regions with DNA copy 
gain and loss were identified using GISTIC, version 2.0.14,15
Identification of Significantly Mutated Genes
Significantly mutated genes were identified according to 
a previously reported protocol.16 The length of the total coding 
sequence regions was represented as N (approximately 39.8 
mb). When a patient (patient i) harbored a total of m
i
 single 
nucleotide variants (SNVs), the probability that the patient 
harbored SNVs in gene t (length: n) was calculated as follows:
Pt i,
( )( / )= − −1 1 m Ni
n t
The sum of P
t,i
 in 51 samples was represented as the 
expected number of cases with SNVs in gene t:
P m Ni
n
t
i
= − −
=
∑ ( ( / ) )( )1 1
1
51
t
The p values of the observed number were calculated 
using the binomial probability function with R pbinom.
Cancer Census Genes and Analysis 
of Hot Spot Mutations
We defined the cancer census genes as follows: 487 
genes listed in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database (release version 64; http://cancer.sanger.
ac.uk/cancergenome/progects/cosmic/) and 13 genes reported 
by Peifer et al.7 were considered candidate driver genes. To 
analyze hot spot mutations, mutation data from the SCLC 
cases were downloaded from the COSMIC database (release 
version 64 or 68).
Cell Lines and Assays
The cell lines were cultured in RPMI-1640 supple-
mented with 10% fetal bovine serum (FBS) or hydrocorti-
sone, insulin, transferrin, estradiol, and selenium (HITES) 
medium with 5% FBS. Then, 10,000 cells were plated in three 
replicates into 96-well plates. After 72 hours incubation with 
inhibitors, cell viability was analyzed with a WST-8 assay and 
a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). Western 
blotting was performed as described in the Supplemental 
Information section (Supplemental Digital Content 1, http://
links.lww.com/JTO/A625).
RESULTS
Patient Characteristics
The characteristics of the available patient exome data 
(n = 51) are summarized in Table 1 and Supplemental Table 3 
(Supplemental Digital Content 3, http://links.lww.com/JTO/
A627). Fifty patients received surgical resections and one patient 
received a mediastinoscopy. Forty-two patients were male and 
nine were female. The median age at the time of surgical resec-
tion was 67 years (range, 42–86 years). Of the 51 patients, 50 
(98%) had a history of smoking, and the pathological stages 
were distributed as follows: stage I, 28 patients; stage II, 13 
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patients; stage III, nine patients; and stage IV, one patient. All 
patients were positive for at least one of the following neuro-
endocrine markers: CD56, chromogranin A, or synaptophysin.
Somatic Point Mutations
The exome capture, sequencing, and analysis of the 51 
SCLC tumor–normal tissue pairs identified 10,640 protein-
altering somatic mutations, including 9376 missense, 707 
nonsense, and 557 protein-altering insertions and/or dele-
tions (INDEL) (Supplemental Table 4, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A627). The SCLC 
tumors had an average of 209 protein-altering SNVs (range, 
41–639) per case, with a mean nonsynonymous mutation 
rate of 6.15 mutations per mega-base (Supplemental Figure 
2, Supplemental Digital Content 2, http://links.lww.com/
JTO/A626). Significantly mutated genes are determined as 
Supplemental Table 5 (Supplemental Digital Content 3, http://
links.lww.com/JTO/A627). Overall, 414 genes had a p value of 
less than 0.01 and 1321 genes had a p value of less than 0.05.
A description of the significantly mutated cancer census 
genes (p value <0.05 in our data set) is provided in Table 2. 
Notably, TP53 was the most frequently mutated gene (muta-
tion frequency of 80%, p value of 5.81E–69). The mutation 
frequencies and p values of cancer census genes were 39% and 
6.42E–22, 16% and 0.00019, 10% and 0.0017 for RB1, ROS1, 
and RET, respectively. Mutations of histone modifiers were 
also recurrently identified in this study; CREBBP was mutated 
in 6% of the patients, and EP300 was mutated in 4% of the 
patients (Fig. 1). Recently reported candidate driver genes were 
also recurrently identified in the PI3K/AKT/mTOR signaling 
pathway. Three patients (6%) had mutations in PIK3CA (one 
E545K, two others), and two patients (4%) had mutations in 
the PTEN C2 domain (Supplemental Figure 3, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A626).
To validate the whole exon sequencing data, we performed 
Sanger sequencing for the variants including four SNVs of 
PIK3CA and ROS1 and a deletion of KIT in five individual tumor 
samples. All the variants detected using whole exon sequenc-
ing were reproduced using conventional Sanger sequencing 
(Supplemental Figure 4, Supplemental Digital Content 2, http://
links.lww.com/JTO/A626). Furthermore, we designed a custom 
target-capturing panel containing all the coding exons of 244 
genes. Four tumor samples were applied to the target resequenc-
ing, and all 41 SNVs or indels in these tumor genomes were 
reproducibly identified (Supplemental Table 6, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A627).
Copy Number Analysis
Next, we applied a novel algorithm to identify the signif-
icant somatic copy number alterations (Supplemental Figure 
5, Supplemental Digital Content 2, http://links.lww.com/JTO/
A626). A description of frequently amplified cancer census 
genes (GISTIC –log
10
 q score ≥1.50) is provided in Table 3. 
MYC family members were frequently amplified (GISTIC 
q scores were 2.50, 1.65, and 1.57 for MYCL1, MYCN, and 
MYC, respectively). The amplifications affected MYCL1 (4/47 
cases), MYC (1/47 cases), and MYCN (1/47 cases). All MYC 
family member amplifications (13% of cases) were mutually 
exclusive (Fig. 1). In addition, gene amplifications were fre-
quently found in the PI3K/AKT/mTOR signaling pathway 
(GISTIC q scores were 2.45 and 1.22 for AKT2 and RICTOR, 
respectively). The gene amplifications in PI3K/AKT/mTOR 
signaling were observed in AKT2 (4/47 cases) and RICTOR 
(3/47 cases), and they were also mutually exclusive (Fig. 1). 
Previously reported amplifications involving SOX2 (1/47 
cases) and KIT (1/47 cases) were also identified.
Recurrent Mutations at the Same Position
Forty genes with recurrent somatic mutations at the 
same position were identified in this study and the COSMIC 
database (Table 4). TP53, the well-characterized tumor sup-
pressor gene, had 29 different positions that mutated more 
than or equal to two times (total recurrent samples, 134). RB1 
had four different positions that mutated two or three times. 
The remaining 38 genes had one position that mutated two or 
three times. Well-established activating mutations in PIK3CA, 
the catalytic subunit of phosphoinositide-3 kinase (E545), 
were also detected in another SCLC cohort.
PI3K/AKT/mTOR Pathway Alteration
Because of the large number of somatic point mutations 
and focal amplifications found in the PI3K/AKT/mTOR sig-
naling pathway (e.g., PIK3CA, PTEN, AKT2, and RICTOR), 
we focused our investigation on the changes in the PI3K/AKT/
mTOR pathway. We observed that the PI3K/AKT/mTOR 
pathway was altered in 17/47 (36%) of the SCLC tumors 
(Fig. 1), and all altered genes in the PI3K/AKT/mTOR path-
way were mutually exclusive. There was no difference in the 
TABLE 1.  Patient Characteristics
Characteristic No. of Patients
Total 51
Gender
  Male/female 42/9
Age, years
  Median (range) 67 (42–86)
Performance status
  0/1/2 35/15/1
Smoking status
  Never/ever 1/50
Pack years
  Median (range) 47 (0–98)
Histology
  Pure SCLC/combined SCLC 40/11
Pathological stage
  I/II/III/IV 28/13/9/1
Vascular invasion
  Absent/present 8/43
Lymphatic invasion
  Absent/present/unknown 31/19/1
Pleural invasion
  Absent/present/unknown 31/19/1
Tumor diameter
  Median (range) 2.5 (1.1–13.0)
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clinical characteristics, such as smoking status, gender, and 
age, between the PI3K/AKT/mTOR pathway-affected group 
(Group A) and the PI3K/AKT/mTOR pathway-unaffected 
group (Group B). The frequencies of TP53 and RB1 mutations 
were identical between Group A and Group B. However, more 
MYC family genes tended to be amplified in Group B; Group 
A did not harbor KRAS or BRAF mutations, and most patients 
in Group A did not have MAPK/ERK pathway changes.
The correlation between the PI3K/AKT/mTOR path-
way changes and RTKs is shown in Supplemental Figure 6 
(Supplemental Digital Content 2, http://links.lww.com/JTO/
A626). The changes in various targetable RTK genes were 
detected, such as ERBB2 (n = 4), KIT (n = 2), PDGFRA 
(n = 3), PDGFRB (n = 2), KDR (n = 3), MET (n = 1), ROS1 
(n = 8), and RET (n = 5). However, none of these genes showed 
a recurrent mutation at the same point in this data set or the 
COSMIC database. The PI3K/AKT/mTOR pathway status did 
not correlate with the RTK changes.
Drug Sensitivity
To further investigate whether the PI3K/AKT/mTOR 
pathway could be a feasible therapeutic target in SCLC, we 
tested the in vitro drug sensitivity of the SCLC cell lines using 
the clinically developed compounds targeting this pathway 
(Fig. 2 and Supplemental Figure 7, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A626). We selected 
three SCLC cell lines with genetic alterations in the PI3K/
AKT/mTOR pathway: H446 (PTEN-loss, MYC-amplified), 
H1048 (PIK3CA mutation), and H1694 (AKT3-amplified). 
We also examined H82 (MYC-amplified) and H209, which 
do not display activation of the PI3K/AKT/mTOR pathway. 
Using these cell lines, we assessed the efficacy of four com-
pounds that inhibit the PI3K/AKT/mTOR pathway and are in 
on-going phase I/II trials: BEZ235 (PI3K and mTOR inhibi-
tor), BKM120 (PI3K inhibitor), INK128 (mTOR inhibitor), 
and MK2206 (AKT inhibitor), as well as one cytotoxic agent, 
cisplatin. None of the cell lines showed apparent cytotoxic-
ity in response to doses up to 1 μM cisplatin. Conversely, 
all PI3K/AKT/mTOR inhibitors significantly impaired the 
proliferation of the SCLC cell lines. H1048, which harbors 
a PIK3CA mutation (H1047R), was the most sensitive to all 
of the PI3K/AKT/mTOR inhibitors, with IC50 values of 3.8, 
5.4, 99.9, and 195.4 nM for INK128, BEZ235, MK2206, 
and BKM120, respectively. BEZ235 was the most effec-
tive compound to specifically inhibit H1048 cell growth 
TABLE 2.  Significantly Mutated Cancer Census Genes (*p < 0.05 in This Study)
This Data Set (n = 51) COSMIC Database
Symbol Mutated Case
Mutation  
Frequency (%) p Value* Mutated Case/Total
Mutation  
Frequency (%)
TP53 41 80 5.81E–69 235/308 76
RB1 20 39 6.42E–22 99/181 55
ROS1 8 16 0.00019 7/65 11
RET 5 10 0.0017 4/147 3
IKZF1 4 8 0.0017 0/57 0
CD79B 2 4 0.0042 0/61 0
PAX7 3 6 0.0074 3/63 5
HIP1 4 8 0.0076 1/62 2
CDH11 4 8 0.0086 0/62 0
MN1 4 8 0.014 1/61 2
PTEN 2 4 0.017 39/309 13
ERBB2 4 8 0.018 1/167 1
LPP 3 6 0.019 0/62 0
MLL2 6 12 0.021 7/57 12
BCL11B 3 6 0.022 0/63 0
LMO1 1 2 0.023 0/62 0
NR4A3 3 6 0.028 1/56 2
ZNF521 4 8 0.031 10/62 16
PIK3CA 3 6 0.034 38/272 14
WT1 2 4 0.040 1/127 1
TRIM33 3 6 0.041 1/62 2
PBRM1 4 8 0.042 1/61 2
FUS 2 4 0.043 0/62 0
ABL1 3 6 0.044 2/63 3
RPN1 2 4 0.045 0/57 0
BTG1 1 2 0.045 0/62 0
*p value., P binom.
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(IC50 = 5.4), with an IC50 value greater than 10-fold lower 
than that of H82 (IC50 = 58.3 nM) and fivefold lower than that 
of H209 (IC50 = 29.7 nM). In contrast, H446 (IC50 = 33.3 nM) 
and H1694 cells (IC50 = 52.5 nM) were relatively resistant to 
BEZ235 treatment.
The impact of BEZ235 on AKT phosphorylation in 
SCLC cells was investigated using Western blot analysis. AKT 
was activated in the H446 and H1048 cells under these culture 
conditions, and it was effectively inhibited after being treated 
with 10 nM BEZ235. Conversely, constitutive phosphorylation 
of AKT was not observed in H1694 cells, even when pan-AKT 
was over-expressed. In addition, AKT phosphorylation was not 
detected in the H82 and H209 cells. Regarding factors located 
downstream of mTOR, S6RP was phosphorylated in all five 
SCLC cell lines. Especially, the phosphorylation level was 
high in AKT-activated H446 and H1048 cells. BEZ235 signifi-
cantly reduced the phosphorylation of S6RP in all the cells.
To evaluate the contribution of PI3K/AKT/mTOR sig-
naling to SCLC cell proliferation, we used RNA interfer-
ence (RNAi) to down-regulate the expression of PIK3CA in 
H1048 cells. The transient silencing of PIK3CA impaired the 
phosphorylation of AKT and S6RP (Supplemental Figure 8, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A626). In addition, PIK3CA silencing induced a decrease in 
the proliferation of H1048 cells.
PY
Sex 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1
2 PTEN
4 AKT2
2 AKT3
4 RICTOR
2 mTOR
4 MYCL1
2 MYCN
1 MYC
1 KRAS
1 BRAF
2 MEK1
2 ERK2
37 TP53
21 RB1
5 CCNE1
2 CREBBP
2 EP300
PIK3CA3
PI3K/Akt/mTOR pathway not altered samples
MYC family* MYC family not altered samplesN Symbol PI3K/Akt/mTOR pathway altered samples
in-frame indel
missense mutation
copy number gain
copy number loss
nonsense mutation
frame-shift indel
0-19 pack year
20-39 pack year
40-59 pack year
60- pack year
1 male
female
FIGURE 1.  An overview of the key driver mutations and major associated clinical features of 47 SCLC samples. The number 
of events per gene is noted on the left. The genes are displayed as rows, and the samples are displayed as columns, with major 
associated clinical features.
PY, PACK YeARS; MYC fAMILY*, MYC fAMILY ALTeRed SAMPLeS.
TABLE 3.  frequently Mutated Cancer Census Genes (–log10 
q score ≥1.5)
Symbol
This Data Set (n = 47)
–log
10
 (q score)
MYB 3.40
 MYCL1 2.50
AKT2 2.45
CLTCL1 2.34
LIFR 2.21
IL7R 2.13
THRAP3 2.09
ETV5 2.05
BCL6 1.99
EIF4A2 1.93
LPP 1.89
PAX5 1.89
ZNF384 1.86
ARID1A 1.65
MYCN 1.65
FANCG 1.65
MYC 1.57
MDS2 1.52
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TABLE 4.  The Recurrent Mutations detected at the Same Position in This Study and the COSMIC database
Gene Recurrent in This Study (no.)
No. in 
This 
Data  
Set Recurrent in COSMIC Database (no.)
No. in 
COSMIC 
Database Total
TP53 Q38 (1) T155 (1) V157 (1) R158 (2) A159 (1) M160 (1) 37 Q38 (1) T155 (4) V157 
(11)
R158 (3) A159 (1) M160 (1) 97 134
A161 (1) Y163 (2) R175 (1) C176 (2) H179 (1) Q192 (1) A161 (1) Y163 (2) R175 (4) C176 (2) H179 (7) Q192 (2)
D208 (1) R209 (1) R213 (1) S215 (2) Y220 (1) R248 (1) D208 (1) R209 (2) R213 (3) S215 (1) Y220 (8) R248 (7)
R249 (2) L265 (1) G266 (2) R273 (1) R283 (2) E286 (1) R249 (11) L265 (1) G266 (3) R273 (8) R283 (1) E286 (5)
E294 (1) E298 (1) Q317 (1) R337 (2) R342 (1) E294 (3) E298 (2) Q317 (1) R342 (1)
RB1 T543 (2) W78 (1) W195 (1) E322 (1) 5 W78 (1) W195 (2) E322 (1) 4 9
ABRA S276 (2) 2 0 2
AP3M2 T72 (2) 2 0 2
CLEC4G R23 (2) 2 0 2
DACT1 V481 (2) 2 0 2
DPP6 Q345 (2) 2 0 2
DUSP27 D886 (2) 2 0 2
GPR149 R540 (2) 2 0 2
KIAA2022 Q738 (2) 2 0 2
OR9G1 C168 (2) 2 0 2
PCDHGA5 E782 (2) 2 0 2
PDE4C P39 (2) 2 0 2
PJA1 E182 (2) 2 0 2
ZFP1 Q287 (2) 2 0 2
B2M M1 (1) 1 M1 (2) 2 3
PIK3CA E545 (1) 1 E545 (2) 2 3
AFF2 D506 (1) 1 D506 (1) 1 2
ASTN1 R184 (1) 1 R184 (1) 1 2
BEND3 G263 (1) 1 G263 (1) 1 2
C8A R438 (1) 1 R438 (1) 1 2
CREB3L3 P82 (1) 1 P82 (1) 1 2
CST4 R46 (1) 1 R46 (1) 1 2
DEFB112 R112 (1) 1 R112 (1) 1 2
GPR139 T322 (1) 1 T322 (1) 1 2
HCN1 Q772 (1) 1 Q772 (1) 1 2
ITGA4 R481 (1) 1 R481 (1) 1 2
JAM3 Y31 (1) 1 Y31 (1) 1 2
KCNJ12 R261 (1) 1 R261 (1) 1 2
LIFR Q978 (1) 1 Q978 (1) 1 2
LRRC52 A258 (1) 1 A258 (1) 1 2
MED23 N1095 (1) 1 N1095 (1) 1 2
MUC6 P27 (1) 1 P27 (1) 1 2
OPN4 C303 (1) 1 C303 (1) 1 2
OR10S1 A283 (1) 1 A283 (1) 1 2
OR2W1 I206 (1) 1 I206 (1) 1 2
OR5F1 S265 (1) 1 S265 (1) 1 2
OR5L1 S267 (1) 1 S267 (1) 1 2
SLC28A3 Q261 (1) 1 Q261 (1) 1 2
ZNF382 C278 (1) 1 C278 (1) 1 2
no., number Recurrent (no.), positions with recurrent mutations (no. of instances).
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DISCUSSION
We performed an integrative genomic analysis of SCLC 
in Japanese patients. The SCLC tumors had a significantly 
high mutation rate. An analysis of the base-level transitions 
and transversions showed that G-to-T transversions were 
predominant (Supplemental Figure 2, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A626), which was con-
sistent with the demonstrated effects of tobacco smoke carcin-
ogens on DNA.8,17 A high prevalence of inactivating mutations 
in TP53 and RB1 and recently reported candidate driver genes, 
including the mutations of histone modifiers (CREBBP7 and 
EP3007), were recurrently observed along with the amplifica-
tion of MYC family members.7,14,18,19 These data indicate that 
the genomic landscape of SCLC is equivalent between Asian 
and Caucasian populations.7,8,17,18
SCLC is characterized by aggressive growth and a poor 
prognosis, and no single molecular targeted drug has shown 
any clinical efficacy over an extended period. A number of 
inhibitors targeting changes in RTKs are currently used in 
clinical use. Alterations in well-known, targetable RTK 
genes, such as ERBB2, KIT, PDGFRA, PDGFRB, KDR, 
MET, ROS1, and RET, were detected in this study. However, 
these alterations did not overlap with previously reported 
activating mutations.
The PI3K/AKT/mTOR signaling pathway is involved 
in the survival, proliferation, and migration of SCLC cell 
lines.13 We confirmed the activation of the PI3K pathway in 
the SCLC-derived cell lines. AKT protein overexpression was 
observed in the AKT3-amplified H1694 cells, and phosphor-
ylated-AKT and S6RP were increased in the PTEN-lacking 
H446 cells and PIK3CA-mutated H1048 cells. In addition, the 
significant decrease in the proliferation of H1048 cells induced 
by PIK3CA silencing suggested that the proliferation of these 
cells was strongly dependent on the PI3K/AKT/mTOR path-
way (Supplemental Figure 8, Supplemental Digital Content 
2, http://links.lww.com/JTO/A626). Consistently, genetic 
changes in the PI3K/AKT/mTOR pathway were detected 
in approximately 40% of our clinical samples. In addition 
to high penetrance, these alterations occurred in a mutually 
exclusive manner. A similar trend was observed in another 
Japanese cohort of primary SCLC (Supplemental Table 7, 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A627). In addition to SCLC, a significant exclusion pattern 
among PI3K pathway molecules was observed in the system-
atic analysis of breast cancer genomes.20 Together, these data 
suggest indispensable roles for this pathway in tumorigenesis.
Two specific inhibitors of mTORC1, everolimus10 
and temsirolimus,11 were tested against SCLC in a Phase 
II study. However, single-agent antitumor activity was lim-
ited in unselected patients; the response rate in these studies 
was less than 10%. To improve the response to these inhibi-
tors, the addition of PI3K inhibition has been suggested. 
The dual inhibition of PI3K and mTOR might be advanta-
geous over single inhibition by suppressing a S6K feedback 
loop that leads to the pathway reactivation.21 Based on this 
idea, an on-going phase I study of the PI3K and mTORC1/2 
dual inhibitor, BEZ235, was designed for the patients with 
advanced solid tumors harboring PIK3CA or PTEN alteration 
(NCT01195376). In this study, we showed that the survival of 
the cisplatin-resistant SCLC cell lines was well suppressed 
by BEZ235, accompanied by the suppression of S6RP phos-
phorylation. Notably, the effect was most significant against 
H1048 cells, which harbor a PIK3CA-activating mutation.
However, we found that not all SCLC cell lines harbor-
ing PI3K/AKT/mTOR pathway alterations exhibited a similar 
sensitivity to BEZ235. Although AKT phosphorylation was 
significantly inhibited by BEZ235 in both the H446 cells and 
H1048 cells, the sensitivity of the H446 cells was less than that 
of the H1048 cells. MYC gene amplification reportedly evades 
PI3K-targeted therapy.22 MYC amplification was demonstrated 
in H446 cells,23,24 and this co-alteration could be one cause of 
the observed low sensitivity. Thus, to determine the most benefi-
cial concentrations for patients, both direct target molecules and 
other interfering signaling pathways should be simultaneously 
assessed. In this study, no surgically resected tumors harbored 
co-alterations of the PI3K/AKT/mTOR pathway and MYC gene 
amplification. However, the sample size of this study and other 
published systemic analyses remained small, and many of the 
samples were obtained from relatively early-stage tumors. We 
should expand the sample size and further analyze samples of 
advanced tumors using biopsy, necropsy, and autopsy specimens 
to clarify the coexistence of oncogenic alterations in SCLC.
B
A
FIGURE 2.  (A) The concentration–response cell survival 
curves of SCLC cell lines with or without genetic alteration in 
the PI3K/AKT/mTOR pathway in response to BeZ235 (nM) 
and Cisplatin (nM). The PIK3CA mutation positive cell line, 
H1048, is relatively sensitive to BeZ235. The H82 and H209 
cell lines are negative controls. (B) Western blotting was used 
to investigate the impact of BeZ235 on AKT phosphoryla-
tion and S6RP phosphorylation in the SCLC cells. AKT was 
activated in H446 and H1048 cells, and it was inhibited after 
being treated with 10 nM BeZ235. AKT was amplified but 
not constitutively phosphorylated in the H1694 cells. AKT 
phosphorylation was not detected in the negative control cell 
lines, H82 and H209. With regard to factors located down-
stream of mTOR, S6RP was phosphorylated in all five SCLC 
cell lines. especially, the phosphorylation level was high in 
AKT-activated H446 and H1048 cells. BeZ235 significantly 
reduced the phosphorylation of S6RP in all the cells.
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Although further large-scale validation studies are 
needed, our data suggest that evaluating the genetic status of 
molecules that modify the PI3K/AKT/mTOR signaling path-
way, such as MYC family and MAPK pathway molecules, is 
essential to select patients with potential sensitivity to PI3K/
AKT/mTOR inhibitors. In other words, enriching the study 
population by performing the integrative genomic analysis 
is essential when performing phase studies of PI3K/AKT/
mTOR inhibitors in SCLC.
In conclusion, the SCLC genome possesses distin-
guishable genetic features in the PI3K/AKT/mTOR pathway. 
Genetic alterations in the PI3K/AKT/mTOR pathway were 
noted as a top therapeutic priority in SCLC. In addition to sur-
gically resected samples, advanced tumors should be exam-
ined for comprehensive genomic analysis.
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